This trial is evaluating whether PDT will improve 3 primary outcomes and 8 secondary outcomes in patients with Carcinoma, Basal Cell. Measurement will happen over the course of Every 30 minutes up to 4 hours.
This trial requires 28 total participants across 1 different treatment group
This trial involves a single treatment. PDT is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Although our results suggest that familial aggregation exists for some cancers, we found no evidence of significant linkage between hereditary breast/ovarian cancer and any specific gene loci. Further studies are needed to explore the relationship between familial cancer and other genes. The ability to identify such genes will facilitate the development of effective diagnostic and preventive methods for hereditary cancers." - Anonymous Online Contributor
"Although it was only observed in one small cohort, we believe that pdt may be useful as a novel therapeutic agent for patients with lung carcinoma." - Anonymous Online Contributor
"Carcinoma may be caused by viral infections (e.g., HPV 16, 18, and 45), bacterial infections (e.g., salmonella, Shiga toxin 1, and bacillus Calmette-Guérin), environmental agents, and hereditary factors (e.g., hereditary nonpolyposis colorectal cancer).\n" - Anonymous Online Contributor
"Different metastatic sites occurred at different times in the disease course; lung, liver, bone, brain, and adrenal were the most common sites of metastases. The distribution of metastases suggested that pulmonary dissemination was more frequent than extrapulmonary dissemination. Recent findings indicated that the incidence of distant metastasis is not constant over time but rather seems to change during the cancer progression process." - Anonymous Online Contributor
"The 5-year survival rate of carcinoma in situ was 22%, which was lower than the 94% 5-year survival rate for invasive carcinoma. Even though this difference was statistically significant, it did not appear to be clinically significant. The survival rate for carcinoma depends largely on the stage at diagnosis; however, the grade of differentiation has a much greater effect on the prognosis of carcinoma." - Anonymous Online Contributor
"The study concluded that the survival rate for node negative carcinoma patients increased up to 5 years after diagnosis instead of 1 year. For node positive carcinoma patients, the survival rate increased till 2 years after diagnosis but then decreased over 3 years. The survival rate was unaffected by other factors such as gender, stage, and biological subtype of carcinoma. Cancer 2015;121:842-850. © 2015 American Cancer Society." - Anonymous Online Contributor
"In a recent study, the mean age at cancer onset was 56.6 years. The percentage of cases occurring during menopause was 32.8%, which suggests that early detection campaigns might benefit women more than men." - Anonymous Online Contributor
"The pdt protein shows a strong correlation with angiogenesis, tumor cell proliferation, and metastasis. Therefore, pdt could be an attractive target for antiangiogenic cancer therapy." - Anonymous Online Contributor
"The signs of carcinoma are nonspecific but commonly include skin changes (rough, scaly patches) and weight loss. They can produce similar clinical presentations to those seen in inflammatory conditions, including hyperlipaemia, arthritis and dermatitis." - Anonymous Online Contributor
"Recent findings suggest that [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) may be the result of numerous environmental factors that are not disclosed by our current understanding of its etiology. Recent findings may explain why we see a large number of cancers, including breast cancer, occurring among the same group of women." - Anonymous Online Contributor
"Recent findings of this survey suggest that the majority of clinicians think that participation in clinical trials for carcinoma is beneficial and would be willing to consider participating in a clinical trial." - Anonymous Online Contributor